Tandem Diabetes Care announced today that it launched its next-generation Control-IQ+ automated insulin delivery algorithm in the U.S.

It has been about a month since the last earnings report for Tandem Diabetes Care, Inc. (TNDM). Shares have lost about 8.9% in that time frame, underperforming the S&P 500. Will the recent negative ...

Tandem Diabetes Care, Inc. announced NEJM publication of positive results from Control-IQ+ AID technology pivotal trial in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Abbott, Dexcom, Insulet, Medtronic and others are developing next-gen sensors, pumps and algorithms for type 2 diabetes ...

Tandem Diabetes Care (Nasdaq:TNDM) today announced positive data supporting its automated insulin delivery technology for type 2 diabetes.

Citigroup cut Tandem Diabetes Care from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $35.00 to $24.00 in a research note on Tuesday, March 4th.

CMO Jordan Pinsker said Tandem hopes to expand Medicare coverage of its automated insulin delivery systems using new data shared at ATTD.

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...

– Additional data presented at the 18th International Conference on Advanced Technologies & Treatments for Diabetes – Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and ...